Johnson & Johnson (JNJ) Stock Analysis
Johnson & Johnson is a diversified healthcare conglomerate operating in pharmaceutical innovation, medical devices, and surgical technologies across global markets. Investors research JNJ for its dual-segment revenue model, dividend history, and exposure to aging demographics and chronic disease treatment.
Get a full AI research report on JNJ
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Johnson & Johnson do?
JNJ operates through two primary segments: Innovative Medicine, which develops and sells prescription pharmaceuticals in oncology, immunology, neuroscience, and infectious disease; and MedTech, which manufactures surgical instruments, orthopedic devices, cardiovascular products, and vision-care solutions sold to hospitals, physicians, and healthcare systems worldwide. Revenue flows through direct sales to healthcare professionals, wholesalers, distributors, and retailers. The company's profitability is supported by a gross margin of 67.8% and operating margin of 25.1%, reflecting pricing power in regulated healthcare markets.
Bull case
- ✓Forward P/E of 21.8x is substantially lower than trailing P/E of 38.8x, suggesting market expectations for earnings growth recovery or normalization in coming years.
- ✓Operating margin of 25.1% and gross margin of 67.8% demonstrate pricing power and operational efficiency typical of established pharmaceutical and medical device leaders.
- ✓Dividend yield of 2.1% with a 60.7% payout ratio indicates sustainable income generation with room for dividend growth without straining cash flow.
- ✓Dual-segment diversification across innovative medicines and medical devices reduces dependence on any single therapeutic area or product category.
- ✓Exposure to aging populations and chronic disease prevalence in developed and emerging markets provides structural tailwinds for demand.
Bear case
- ✗Trailing P/E of 38.8x is elevated relative to historical averages for the healthcare sector, raising questions about current valuation relative to near-term earnings.
- ✗Debt-to-equity ratio of 57.7% indicates meaningful financial leverage, which constrains balance sheet flexibility and increases refinancing risk in rising rate environments.
- ✗PEG ratio of 2.77 suggests the stock may be priced at a premium relative to expected earnings growth rates, depending on growth assumptions.
- ✗Pharmaceutical revenue faces ongoing patent cliff risks as blockbuster drugs lose exclusivity, requiring continuous innovation to offset revenue declines.
- ✗Regulatory and litigation risks in healthcare, including drug pricing pressures and product liability claims, create unpredictable cost headwinds.
JNJ valuation & financial health
Johnson & Johnson trades at a trailing P/E of 38.8x with a forward P/E of 21.8x, indicating the market is pricing in earnings expansion. The company's price-to-book ratio of 7.2x reflects premium valuation typical of established healthcare leaders with strong brands and recurring revenue. Gross margins of 67.8% and operating margins of 25.1% demonstrate operational leverage and pricing power. However, the debt-to-equity ratio of 57.7% signals substantial leverage, and the PEG ratio of 2.77 suggests valuation may be elevated relative to growth expectations. The 2.1% dividend yield with a 60.7% payout ratio indicates sustainable shareholder returns without overextension.
The bottom line
Johnson & Johnson presents a classic tension between quality and valuation. The company's diversified business model, strong margins, and dividend history appeal to income-focused and defensive investors; however, the elevated trailing P/E and leverage ratio warrant careful consideration of entry points and growth assumptions. Key factors to weigh include the sustainability of earnings growth given patent expirations, the company's ability to manage debt levels, and whether forward earnings justify current multiples. Monitoring quarterly earnings beats, pipeline progress in key therapeutic areas, and debt reduction initiatives will be important for assessing whether valuation risk is offset by fundamental strength.
Frequently asked questions
What does Johnson & Johnson do?
JNJ operates in two main segments: Innovative Medicine (prescription pharmaceuticals for oncology, immunology, neuroscience, and infectious disease) and MedTech (surgical instruments, orthopedic devices, cardiovascular products, and vision care). The company sells to hospitals, physicians, wholesalers, and healthcare systems globally.
Is JNJ a dividend stock?
Yes, JNJ pays a dividend with a current yield of 2.1% and a payout ratio of 60.7%, indicating sustainable income generation. The company has a long history of dividend payments and increases, making it popular with income-focused investors.
What is JNJ's valuation compared to peers?
JNJ's trailing P/E of 38.8x is elevated, but the forward P/E of 21.8x suggests the market expects earnings growth. The price-to-book ratio of 7.2x reflects premium valuation typical of established healthcare leaders, though comparisons to sector peers require analyzing their specific growth and margin profiles.
What are the main risks for JNJ investors?
Key risks include patent expirations on blockbuster drugs, a debt-to-equity ratio of 57.7% that limits financial flexibility, regulatory and pricing pressures in healthcare, and litigation exposure. The elevated trailing P/E also means valuation risk if earnings growth disappoints.
How profitable is Johnson & Johnson?
JNJ demonstrates strong profitability with a gross margin of 67.8%, operating margin of 25.1%, and net margin of 16.2%, reflecting pricing power and operational efficiency in pharmaceuticals and medical devices. These margins are typical of established healthcare leaders with strong brand portfolios.
Is JNJ overvalued?
The trailing P/E of 38.8x is elevated, but the forward P/E of 21.8x and PEG ratio of 2.77 require context on expected earnings growth rates and sector comparables. Whether valuation is justified depends on your assumptions about future earnings growth, competitive positioning, and acceptable risk-return tradeoffs.
Research JNJ with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.